

SIGACHI LABORATORIES LIMITED

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273,

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN:L24230TG1994PLC018786

Statement Of Un-Audited Financial Results for the Quarter ended 30th June, 2018

(Rs. In Lakhs)

Sl.No.	PARTICULARS	Quarter ended			Year Ended
		30.06.2018	31.03.2018	30.06.2017	31.03.2018
		Un Audited	Audited	Un Audited	Audited
1	Revenue from Operations	30.19	19.22	47.20	176.24
2	Other Income	1.68	13.80	-	32.86
3	Total Revenue (1+2)	31.87	33.02	47.20	209.10
4	Expenses				
	a) Cost of Materials consumed	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-
	c)Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	-	-	-	-
	d) Employee benefits expenses	5.56	7.57	6.35	28.29
	e) Finance Costs	-	-	-	-
	f) Depreciation and Amortisation expenses	4.01	3.57	2.78	12.59
	g) Other Expenses	3.38	7.46	3.78	34.32
	Total Expenses	12.95	18.60	12.91	75.20
5	Profit/(Loss) before exceptional and extraordinary items and tax (3 - 4)	18.92	14.42	34.29	133.90
6	Exceptional items	-	-	-	-
7	Profit/(Loss) before extraordinary items and tax (5 - 6)	18.92	14.42	34.29	133.90
8	Extraordinary items	-	-	-	-
9	Profit/(Loss) before tax (7 - 8)	18.92	14.42	34.29	133.90
10	Tax Expense :				
	(a) Current tax	4.25	5.19	4.25	23.00
	(b) Deferred tax	0.55	(0.48)	0.55	(0.20)
	Total Tax Expense	4.80	4.71	4.80	22.80
11	Profit/(Loss) for the period (9-10)	14.12	9.71	29.49	111.10
12	Other comprehensive income (OCI)				
	(a) Items that will not be reclassified to profit or loss	(16.13)	(69.65)	24.87	75.00
	(b) Items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive income	(16.13)	(69.65)	24.87	75.00
	Total Comprehensive income for the period(11+12)	(2.01)	(59.94)	54.36	186.10
13	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	675.31	675.31	675.31	675.31
14	Other Equity	-	-	-	1,249.73
15	Earnings Per Share (of Rs.10/- each) (not annualized)				
	a) Basic	0.21	0.14	0.44	1.65
	b) Diluted	0.21	0.14	0.44	1.65

Segment wise Revenue, Results and Capital Employed for the Quarter ended 30th June, 2018

(Rs.in Lakhs)

SI.No.	Particulars	Quarter Ended			Year Ended
		30.06.2018	31.03.2018	30.06.2017	31.03.2018
		(Unaudited)	Audited	(Unaudited)	Audited
1	Segment Revenue				
	a) Bulk Drugs and Intermediates	17.00	34.00	24.00	112.10
	b) Investments	14.87	(0.98)	23.20	97.00
	Total	31.87	33.02	47.20	209.10
	Less: Inter Segment Revenue	-	-	-	-
	Net sales/Income From Operations	31.87	33.02	47.20	209.10
2	Segment Results Profit/ (Loss) before tax and finance Cost from each segment				
	a) Bulk Drugs and Intermediates	12.17	29.95	20.39	93.14
	b) Investments	14.87	(0.98)	23.20	97.00
	Total	27.04	28.97	43.59	190.14
	Less: (i) Finance Costs	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	8.12	14.55	9.30	56.24
	(iii) Un-allocable income	-	-	-	-
	Total Profit Before Tax	18.92	14.42	34.29	133.90
3	Capital Employed				
	(Segment assets – Segment Liabilities)				
	a) Bulk Drugs and Intermediates	326.67	409.75	328.80	409.75
	b) Investments	1,652.11	1,571.04	1,514.29	1,571.04
	Total	1,978.78	1,980.79	1,843.09	1,980.79

Notes:

- The company adopted Indian Accounting Standards (IND AS) from 1st April, 2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- The above Financial results reviewed by the Audit Committee were considered and approved by the Board of Directors at their respective meetings held on 14.08.2018.
- The Standalone Financial results are reviewed by the Statutory Auditors of the Company as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015.
- Previous period(s) /Year(s) figures have been re-grouped/re-classified/re-arranged wherever necessary.

By Order of the Board
for SIGACHI LABORATORIES LIMITED

Place: Hyderabad
Date: 14.08.2018

(T. R. Sekhar)
Executive Director
DIN:02943146

INDEPENDENT AUDITORS' REVIEW REPORT

To
The Board of Directors
Sigachi Laboratories Limited
Hyderabad

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Sigachi Laboratories Limited ("the company") for the quarter ended 30th June, 2018 ("the statement"), being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 5th July, 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these interim financial statements based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the interim financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 14.08.2018
Place: Hyderabad

For Niranjan & Narayan
Chartered Accountants
FRN:005899S

UVSSeshadri
Partner - Membership No.210673